Drug · DIN 02461528
BASAGLAR
KWIKPEN - DELIVERS UP TO 80 UNITS PER INJECTION
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 18, 2017; first marketed August 18, 2017.
- Drug Identification Number (DIN)
- 02461528
- Company (DIN owner)
- Eli Lilly Canada IncToronto, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Insulin glargine A10AE04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| INSULIN GLARGINE | 100 UNIT | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 10, 2017: NOC 18951Supplement to a New Drug Submission (SNDS) · Addition of a secondary container closure system
Other DINs named BASAGLAR
- DIN 02444844 · Marketed
- DIN 02444852 · Cancelled Post Market